MedTrace Logo

REmote iSchemic condItioning in Lymphoma PatIents REceiving ANthraCyclinEs

NCT05223413 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 608

Last updated 2025-09-18

No results posted yet for this study

Summary

Multinational, prospective, proof of concept phase II, double-blinded, sham-controlled, randomized clinical trial (RCT) to evaluate the efficacy and safety of Remote Ischaemic PreConditioning (RIPC) in Lymphoma patients receiving anthracyclines.

Conditions

  • Anthracycline-induced Cardiac Toxicity
  • Lymphoma

Interventions

DEVICE

RIPC

The procedure will be performed by using an electric auto-control device (modified blood pressure monitor for remote ischemic conditioning, Seagull Healthcare Aps, Denmark) for Remote Ischemic Conditioning in the arm. During the inflation period, the blood pressure cuff is inflated to 200 mmHg to stop blood flow in the arm.

DEVICE

Simulated RIPC (Sham)

The procedure will be performed by using an electric auto-control device (modified blood pressure monitor for remote ischemic conditioning, Seagull Healthcare Aps, Denmark) for Remote Ischemic Conditioning in the arm. During the inflation period, the blood pressure cuff is inflated to a low pressure not stopping blood flow in the arm.

Sponsors & Collaborators

  • European Commission

    collaborator OTHER

  • Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III

    lead OTHER

Principal Investigators

  • Borja Ibañez, MD PhD FESC · CNIC

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-01-18
Primary Completion
2026-06-30
Completion
2026-12-31

Countries

  • Denmark
  • France
  • Germany
  • Netherlands
  • Portugal
  • Spain

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05223413 on ClinicalTrials.gov